Related Experiment Video
Updated: May 10, 2026
11:00
Untargeted Metabolomics from Biological Sources Using Ultraperformance Liquid Chromatography-High Resolution Mass Spectrometry (UPLC-HRMS)
Published on: May 20, 2013
Targeting MET: why, where and how?
1University of Torino, Department of Oncology, Institute for Cancer Research at Candiolo, 10060 Candiolo, Torino, Italy. elena.ghiso@ircc.it
Current Opinion in Pharmacology
|June 26, 2013
Summary
Targeted cancer therapies show promise, focusing on receptor tyrosine kinases (RTKs). The MET/HGF pathway is a key target, with inhibitors offering new treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Targeted therapies offer a new approach to cancer treatment.
- Receptor tyrosine kinases (RTKs) are crucial targets for cancer therapy.
- The MET/HGF pathway is increasingly recognized as a significant target in oncology.
Purpose of the Study:
- To explore the rationale for targeting the MET/HGF pathway in human tumors.
- To identify specific cancer types where MET/HGF inhibition is beneficial.
- To review methods for inhibiting MET and HGF in cancer treatment.
Main Methods:
- Literature review of the MET/HGF pathway in cancer.
- Analysis of the role of MET/HGF in tumor development.
- Examination of therapeutic strategies targeting MET/HGF.
Main Results:
- The MET/HGF pathway plays a critical role in various human tumors.
- MET/HGF inhibition shows potential across different cancer indications.
- Both monoclonal antibodies and tyrosine kinase inhibitors are viable approaches for MET/HGF targeting.
Conclusions:
- The MET/HGF pathway is a validated target for novel cancer therapies.
- Targeted inhibition of MET/HGF presents a promising therapeutic avenue.
- Further research is needed to address outstanding questions in anti-MET/HGF therapy.
Related Concept Videos
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
02:30Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...